Anavex Blarcamesine is expected to work in multiple CNS diseases, they are way ahead of Synaptogenix and the compound is much less expensive. I believe they will make Bryostatin obsolete.
A successful Parkinson's Dementia trial foreshadows a successful Alzheimer's trial.
The 48 week Alzheimer's trial is expected to end in May..